Life Expectancy After Liver Resection: What to Expect

Survival after liver resection depends heavily on why the surgery was performed, the health of the remaining liver, and the biology of any underlying cancer. For colorectal cancer that has spread to the liver, median survival after resection now reaches roughly five years, with about three in ten patients alive at the decade mark. For primary liver cancers like hepatocellular carcinoma, five-year survival after resection ranges widely, from around 25% to over 60%, depending on tumor stage and liver function. These numbers have improved steadily over recent decades, but the range is wide enough that a single “life expectancy after liver resection” figure is essentially meaningless without knowing the details of your specific situation.

How Dangerous Is the Surgery Itself

The immediate concern for anyone facing liver resection is surviving the operation and the weeks that follow. The liver is one of the most blood-rich organs in the body, and removing a sizable portion of it is major surgery by any standard. Historically, surgeons tracked 30-day mortality, but the field has increasingly shifted to 90-day mortality because many serious complications, especially liver failure, can declare themselves weeks after the patient leaves the hospital.

In a large study of over 500 patients undergoing major liver resection, 90-day mortality was about 11%. The patients at highest risk were those aged 65 or older, those with diabetes, those with a primary liver cancer diagnosis, those with worse baseline health status, and those who had the most extensive operations (extended hemihepatectomy, meaning removal of more than half the liver plus additional segments).¹ A separate study focused specifically on hepatocellular carcinoma found that older age, kidney problems, worse liver function scores, vascular invasion by the tumor, and resection of three or more liver segments were all independent predictors of death within 90 days.²

Not all liver resections carry the same operative risk. Removing a small wedge of tissue from a healthy liver is a different proposition than taking out four or five segments from a cirrhotic one. In series focused on patients with better liver function and less extensive resections, 90-day mortality has been reported as low as 2%.³ The gap between 2% and 11% reflects how much the underlying liver disease, the extent of surgery, and baseline patient health matter.

Post-Hepatectomy Liver Failure and Why It Matters Long Term

The complication surgeons worry about most is post-hepatectomy liver failure, which happens when the liver remnant cannot keep up with the body’s metabolic demands. This is graded in severity: mild cases (grade A) often resolve on their own, while moderate-to-severe cases (grade B and C) can require intensive care and carry a real risk of death. Post-hepatectomy liver failure does not just threaten you in the hospital. A study of major hepatectomy patients found that clinically significant liver failure (grade B or C) was independently linked to worse long-term survival, roughly doubling the hazard of death over subsequent years, while mild liver failure was not.⁴

How this plays out in practice varies by the underlying disease. In one study of hepatocellular carcinoma patients, those who developed liver failure had one-year survival of about 73%, compared with 94% for those who did not. By five years the gap narrowed, with survival of roughly 52% versus 54%, suggesting that patients who survive the initial insult of liver failure can still do reasonably well in the long run.⁵ For patients with colorectal liver metastases, a severely elevated bilirubin after surgery (a marker of significant liver injury) was associated with a median survival of only 16 months compared with 58 months in patients without liver failure.⁶

Long-Term Survival for Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common primary liver cancer, and resection remains one of the standard treatments when the tumor is caught at a stage where surgery is feasible and the liver is functioning well enough to tolerate losing tissue. Five-year survival figures vary widely across studies and time periods. An older series from the 1990s reported five-year survival of about 26% and ten-year survival of roughly 19%.⁷ Another study of 87 patients who underwent curative resection reported overall five-year survival of about 39%.⁸

More recent data tend to be more encouraging. A review of elderly patients with hepatocellular carcinoma found five-year survival rates after resection ranging from 26% to 76%, with the wide spread reflecting differences in tumor stage, liver function, and patient selection.⁹ The trend over decades is clearly upward, driven by better patient selection, improved surgical technique, and the recognition that liver function scores matter at least as much as tumor size. A liver function measure called the ALBI grade, based simply on albumin and bilirubin levels, has proven to be a strong predictor of who will do well after surgery and who will not.¹⁰ In one large analysis, ALBI grade measured a year after resection was an independent predictor of both recurrence and liver-related death.¹¹

Long-Term Survival for Colorectal Liver Metastases

When colorectal cancer spreads to the liver, resecting those metastases is one of the few treatments that can lead to a genuine cure. A large international study estimated median survival for the overall cohort at 59 months (just under five years), with roughly half of patients alive at five years and about 30% alive at ten years. Patients who survived past the ten-year mark were essentially cured, with 98% of them remaining disease-free beyond that point.¹²

These numbers have improved dramatically over the decades. An earlier landmark series found that patients operated on between 1984 and 1992 had a five-year survival of 31%, while those operated on between 1993 and 1999 had a five-year survival of 58%. Overall, the series reported a median survival of 46 months and a ten-year survival of 26%.¹³ The improvement reflects better patient selection, advances in chemotherapy, and refinements in surgical technique including the ability to perform repeat resections.

Not all colorectal liver metastases carry the same prognosis. Several factors predict worse outcomes: age over 60, a large number of metastases, the largest metastasis being over 5 cm, a right-sided primary tumor, and the presence of cancer outside the liver.¹⁴ Tumor genetics also matter. Patients whose tumors carry certain KRAS mutations along with a TP53 mutation had a median survival of about four and a half years, while those with the KRAS mutation but normal TP53 had a median survival exceeding seven years, comparable to patients with no KRAS mutation at all.¹⁵

Cholangiocarcinoma Has a Tougher Outlook

Intrahepatic cholangiocarcinoma, a cancer that arises from the bile ducts within the liver, has notably worse outcomes after resection than either hepatocellular carcinoma or colorectal metastases. One multi-institutional study found that five-year disease-free survival after primary resection was only about 16%.¹⁶ A separate Chinese series of 251 patients reported five-year overall survival of about 32%, seven-year survival of 22%, and ten-year survival of roughly 8%. So while long-term survival is possible, it is considerably less common than with the other indications for liver resection.¹⁷

The Role of Surgical Margins

Whether the surgeon achieves a “clean” margin (meaning no cancer cells at the cut edge of the removed tissue, called R0) has traditionally been considered one of the most important determinants of long-term survival. And broadly speaking, the literature supports this: positive margins (R1) are associated with worse overall survival for colorectal liver metastases.¹⁸ But the picture is more nuanced than a simple clean-versus-not-clean story. Some studies have found that recurrence at the actual surgical margin is no more common after R1 than R0 resection, and that tumor biology, including the presence of certain mutations and the response to preoperative chemotherapy, may be more important than the width of the margin in determining who ultimately survives.¹⁹ This is an active area of debate, and it matters practically because some tumors sit so close to critical blood vessels that achieving a wide margin would mean leaving the patient with too little liver to survive.

How the Liver Bounces Back

One of the remarkable things about liver resection is that the liver can regenerate. In patients with a healthy liver, the remnant can grow back to its original volume within three to six months, and liver function typically normalizes within two to three weeks. However, regeneration is substantially slower and less complete in patients with underlying cirrhosis or chronic hepatitis.²⁰ This is one reason why surgeons are much more conservative about how much liver they remove in patients with chronic liver disease. For patients whose remaining liver is judged too small, a technique called portal vein embolization can be used before surgery to redirect blood flow and stimulate the future remnant to grow in advance. In one series, this approach allowed resection in patients with extensive colorectal metastases, yielding a five-year survival of about 45%.²¹

When Cancer Comes Back

Recurrence is the rule rather than the exception after liver resection for cancer. For hepatocellular carcinoma, recurrence rates are high: roughly half or more of patients develop new tumors within a few years. For patients with hepatitis B-related hepatocellular carcinoma, high viral loads at the time of surgery are linked to more frequent recurrence, and keeping the virus suppressed with antiviral therapy after resection is one of the most straightforward things patients can do to improve their odds.²² High viral loads are also associated with worse liver function over time, which limits future treatment options.²³

When hepatocellular carcinoma does come back, a second liver resection is feasible in selected patients. One study reported five-year survival of 42% after a second resection, which is encouraging and comparable to first-time resection rates in many series.²⁴ The type of recurrence matters: tumors that arise at a new location in the liver (so-called multicentric occurrence, essentially a new cancer rather than a recurrence of the old one) tend to have better outcomes after repeat resection than those that represent spreading from the original tumor.²⁵ Similarly, for colorectal liver metastases, repeat resection of recurrent disease offers a meaningful survival benefit and even the possibility of cure in a small fraction of patients.²⁶

Does Age Rule You Out

Age alone does not disqualify someone from liver resection, but it does shift the risk calculus. A systematic review and meta-analysis comparing elderly patients (65 and older) with younger patients found that overall survival and disease-free survival were statistically similar between the two groups. However, 30-day, 90-day, and in-hospital mortality were all higher in older patients, and the overall complication rate was elevated by about 44%.²⁷ Even patients in their 80s and beyond can do well: a Japanese study found that patients aged 85 or older had one-year survival of about 90% and five-year survival of roughly 49% after liver resection for hepatocellular carcinoma, statistically comparable to patients in their 70s.²⁸ The key is careful selection: older patients who make it through the perioperative period tend to have similar long-term cancer-specific outcomes as younger ones.

Resection Versus Transplant and Ablation

For small hepatocellular carcinomas, resection is not the only option. Liver transplantation replaces the entire diseased liver and eliminates both the tumor and the underlying cirrhosis that gave rise to it. Ablation destroys the tumor with heat or cold without removing tissue. How do these compare? In a study of patients with single small tumors (3 cm or less), overall survival was similar among resection, transplantation, and ablation when analyzed by intention to treat. Disease-free survival was highest for transplant, significantly better than ablation and numerically better than resection, though the latter comparison did not reach statistical significance.²⁹ In a national cohort looking at patients who met transplant criteria, five-year survival was about 71% after transplantation and 64% after resection, a difference that was not statistically significant.³⁰

Transplant has the advantage of removing the diseased liver entirely and avoiding recurrence from the underlying liver disease, but organ availability is a real constraint. Resection is more readily available and does not require waiting on a donor list, which for some patients means getting treated sooner.

Minimally Invasive Liver Surgery

Open liver surgery through a large abdominal incision has been the standard for decades, but laparoscopic and robotic approaches are increasingly common. A prospective study comparing robotic, laparoscopic, and open resection for early-stage hepatocellular carcinoma found no significant differences in five-year disease-free survival (roughly 64%, 54%, and 51% respectively) or overall survival (about 81%, 79%, and 76%).³¹ A separate study using national cancer database data found that robotic surgery was associated with better overall survival than laparoscopic surgery for stage I hepatocellular carcinoma, with five-year survival of 63% versus 45%.³²

Where minimally invasive approaches clearly shine is in short-term recovery. In one matched comparison of robotic versus open resection, robotic patients spent a median of four days in the hospital compared with ten days for open patients, had fewer ICU admissions, fewer severe complications, and far less post-hepatectomy liver failure. Ninety-day survival was similar between the two groups.³³ Not every patient is a candidate for minimally invasive surgery, especially those with very large tumors or tumors in difficult locations, but when it is feasible, the recovery advantages are substantial.

Quality of Life After Surgery

Survival statistics are obviously critical, but what patients often want to know is how they will feel afterward. A prospective study tracking quality of life found that all patients, regardless of whether the resection was for a benign or malignant tumor, showed improvement in global health status at three, six, and twelve months after surgery. Patients with benign disease recovered faster and reported better physical function and less fatigue at every time point, but even those with cancer showed meaningful recovery.³⁴

Enhanced recovery programs, which bundle together changes like early feeding, minimizing opioids, early mobilization, and laparoscopic technique when possible, have shortened functional recovery times. In one study, patients on an enhanced recovery protocol reached functional recovery in about five and a half days compared with nearly seven days for those managed conventionally.³⁵ The combination of laparoscopic or robotic technique with enhanced recovery pathways means that many patients are discharged within a week and back to daily activities within a few weeks, a dramatic change from the era of prolonged hospital stays that characterized liver surgery a generation ago.

Where You Have Surgery Matters

This is one of the clearest and most actionable findings in the liver surgery literature: outcomes are better at hospitals that do more liver resections. A national study of hepatocellular carcinoma patients found that adjusted ten-year survival ranged from about 29% at high-volume academic programs down to about 21% at community cancer programs. Having the surgery performed at a transplant center was also independently associated with better survival.³⁶ The difference reflects not just surgical skill but the entire ecosystem of care: dedicated anesthesiologists, hepatologists managing liver function before and after surgery, interventional radiologists who can handle complications, and multidisciplinary tumor boards deciding who should be operated on in the first place. If your situation permits any choice about where to have the operation, seeking out a high-volume liver surgery center is one of the few decisions within your control that has a measurable effect on long-term survival.

Chemotherapy Before and After Resection

For colorectal liver metastases, chemotherapy is almost always part of the treatment plan, but there has been debate about whether it is better given before and after surgery (perioperative) or only after (adjuvant). At least one direct comparison found that overall survival was essentially identical regardless of the approach, with median survival around 72 months in both groups.³⁷ The broader trend over recent decades has been that combining improved surgical methods with evolving chemotherapy regimens has steadily extended survival for patients with liver metastases from colorectal cancer.³⁸ Ongoing research into targeted therapies, immunotherapy, and biomarker-guided treatment selection continues to reshape this landscape, but resection remains the backbone of any curative-intent strategy for liver-limited metastatic colorectal cancer.